HUB Organoids™ supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF).
HUB Organoids™ advance treatment for Cystic Fibrosis.
Promoting full-length CFTR protein production is a requisite step to address some of the remaining unmet medical need for Cystic Fibrosis (CF) patients carrying the nonsense allele G542X
